

Daré Bioscience in-licenses Juniper's contraceptive ring

26 April 2018 | News | By Priyanka Bajpai

Juniper's novel intravaginal ring technology was developed by Dr. Robert Langer from the Massachusetts Institute of Technology and Dr. William Crowley from Massachusetts General Hospital and Harvard Medical School.



Singapore – Daré Bioscience, a clinical-stage, women's biopharmaceutical company focused on women's sexual and reproductive health, announced it has secured exclusive rights to Juniper Pharmaceuticals' contraceptive intravaginal ring technology, including Juniper's three preclinical candidates. Juniper's novel intravaginal ring technology was developed by Dr. Robert Langer from the Massachusetts Institute of Technology and Dr. William Crowley from Massachusetts General Hospital and Harvard Medical School.

"We see great potential in this promising technology with already established, compelling preclinical results and intellectual property that we believe will support further drug development," said Sabrina Martucci Johnson, Daré's President and Chief Executive Officer. "We believe that the capabilities of the intravaginal ring platform will greatly expand our ability to identify and meet unmet needs in women's sexual and reproductive health."

In addition to its newly acquired platform, Daré has two products currently in clinical development, including its lead candidate Ovaprene, the non-hormonal contraceptive intravaginal ring.

The Juniper intravaginal ring technology allows for sustained drug delivery over time periods ranging from weeks to months. Unlike other vaginal rings, the Juniper intravaginal rings release drugs in a solid ethylene vinyl acetate polymer matrix without the need for a membrane or reservoir to contain the active drug or control the release.